Cost-Effectiveness of Workplace Covid-19 Self-Testing: A Mathematical Modeling Study
Topics in Antiviral Medicine
; 31(2):383-384, 2023.
Article
Dans Anglais
| EMBASE | ID: covidwho-2316143
ABSTRACT
Background:
As COVID-19 cases persist, one potential intervention to reduce absenteeism in the workplace due to COVID-19 is to use rapid antigen diagnostics to mitigate the spread of SARS-CoV-2. Furthermore, routine testing in the workplace offers an avenue to reaching a large proportion of the population which could lead to a greater community impact beyond solely mitigating transmission events that occur in the workplace. We sought to identify the most cost-effective workplace testing strategies at the community level and within individual workplaces. Method(s) We used two models to understand how SARS-CoV-2 AgRDTs could best be implemented within the workplace to mitigate the spread of COVID-19. In our community-level dynamic transmission model, PATAT, we evaluated the impact of symptomatic testing and asymptomatic testing of a fixed proportion of the formally employed workforce on broader community transmission. We stratified runs by asymptomatic testing frequency, vaccine coverage, vaccine effectiveness, and Rt. Simulations were informed using demographic data from Georgia, Brazil, and the Netherlands. We conducted a cost-effectiveness analysis using the results from each country and assumed a $2.50 total cost per test. Result(s) We observed a substantial decrease in the number of infections occurring in both the workplace and community when a SARS-CoV-2 AgRDTs strategy was implemented. Under all conditions, mandatory symptomatic testing and related quarantine from the workplace averted up to 72%, 79%, and 74% of community infections in Brazil, Georgia, and the Netherlands respectively. Limiting tests to symptomatic workers was always on the cost-effectiveness frontier, regardless of the vaccine coverage, efficacy, or Rt of the virus (Figure 1), at $2-$4 per workplace infection prevented. While asymptomatic testing was on the cost-effectiveness frontier, it would cost an additional $500-$6700 to prevent one additional workplace infection. The added benefit of routine asymptomatic testing was minimal until 100% of the workforce was reached. Conclusion(s) We found self-testing with AgRDTs for the formally employed workforce is both efficient at reducing workplace and community infections as well as cost-effective when targeting symptomatic individuals. Willingness to pay to avoid workplace absenteeism may differ by country, individual workplaces, and the perceived economic value of several workdays missed. If there is a higher willingness to pay, routine asymptomatic screening may be considered.
absenteeism; adult; Brazil; community transmission; conference abstract; coronavirus disease 2019; cost effectiveness analysis; demographics; disease simulation; human; Netherlands; nonhuman; prevention; quarantine; self-testing; Severe acute respiratory syndrome coronavirus 2; simulation; Willingness To Pay; worker; workforce; working time; workplace; vaccine
Collection:
Bases de données des oragnisations internationales
Base de données:
EMBASE
Type d'étude:
Études expérimentales
langue:
Anglais
Revue:
Topics in Antiviral Medicine
Année:
2023
Type de document:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS